Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study
Crossref DOI link: https://doi.org/10.1186/s12872-017-0663-6
Published Online: 2017-08-23
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Brown, Alexander J.M.
Lang, Chim
McCrimmon, Rory
Struthers, Allan http://orcid.org/0000-0002-2926-2528
Funding for this research was provided by:
AstraZeneca